Repositorio
Institucional

Yusuf, Salim

Attaei, Marjan W.#Khatib, Rasha#McKee, Martin#Lear, Scott#Dagenais, Gilles#Igumbor, Ehimario U.#AlHabib, Khalid F.#Kaur, Manmeet#Kruger, Lanthe#Teo, Koon#Lanas, Fernando#Yusoff, Khalid#Oguz, Aytekin#Gupta, Rajeev#Yusufali, Afzalhussein M.#Bahonar, Ahmad#Kutty, Raman#Rosengren, Annika#Mohan, Viswanathan#Avezum, Alvaro#Yusuf, Rita#Szuba, Andrzej#Rangarajan, Sumathy#Chow, Clara

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

ELSEVIER SCI LTD

LANCET PUBLIC HEALTH

en

Background Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the association with use of these medicines and blood pressure control in countries at varying levels of economic development. Methods We analysed the availability, costs, and affordability of blood pressure-lowering medicines with data recorded from 626 communities in 20 countries participating in the Prospective Urban Rural Epidemiological (PURE) study. Medicines were considered available if they were present in the local pharmacy when surveyed, and affordable if their combined cost was less than 20% of the households' capacity to pay. We related information about availability and affordability to use of these medicines and blood pressure control with multilevel mixed-effects logistic regression models, and compared results for high-income, upper-middle-income, lower-middle-income, and low-income countries. Data for India are presented separately because it has a large generic pharmaceutical industry and a higher availability of medicines than other countries at the same economic level. Findings The availability of two or more classes of blood pressure-lowering drugs was lower in low-income and middle-income countries (except for India) than in high-income countries. The proportion of communities with four drug classes available was 94% in high-income countries (108 of 115 communities), 76% in India (68 of 90), 71% in upper-middle-income countries (90 of 126), 47% in lower-middle-income countries (107 of 227), and 13% in low-income countries (nine of 68). The proportion of households unable to afford two blood pressure-lowering medicines was 31% in low-income countries (1069 of 3479 households), 9% in middle-income countries (5602 of 65 471), and less than 1% in high-income countries (44 of 10 880). Participants with known hypertension in communities that had all four drug classes available were more likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [OR] 2.23, 95% CI 1.59-3.12), p<0.0001), combination therapy (1.53, 1.13-2.07, p=0.054), and have their blood pressure controlled (2.06, 1.69-2.50, p<0.0001) than were those in communities where blood pressure-lowering medicines were not available. Participants with known hypertension from households able to afford four blood pressure-lowering drug classes were more likely to use at least one blood pressure-lowering medicine (adjusted OR 1.42, 95% CI 1.25-1.62, p<0.0001), combination therapy (1.26, 1.08-1.47, p=0.0038), and have their blood pressure controlled (1.13, 1.00-1.28, p=0.0562) than were those unable to afford the medicines. Interpretation A large proportion of communities in low-income and middle-income countries do not have access to more than one blood pressure-lowering medicine and, when available, they are often not affordable. These factors are associated with poor blood pressure control. Ensuring access to affordable blood pressure-lowering medicines is essential for control of hypertension in low-income and middle-income countries. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Artículo original

Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Canadian Institutes of Health Research Strategy for Patient Oriented Research through the Ontario SPOR Support Unit, the Ontario Ministry of Health and Long-Term Care, pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi Aventis [France and Canada], Boehringer Ingelheim [Germany amd Canada], Servier, and GlaxoSmithKline), Novartis and King Pharma, and national or local organisations in participating countries.

Instituto de Investigación en Salud Poblacional, Institutos Canadienses de Investigación en Salud, Fundación de Corazón y Accidente Cerebrovascular de Ontario, Estrategia de Investigación para la Investigación Orientada al Paciente de los Institutos Canadienses de Salud a través de la Unidad de Apoyo SPOR de Ontario, Ministerio de Salud y Cuidados a Largo Plazo de Ontario, compañías farmacéuticas (con importantes contribuciones de AstraZeneca [Canadá], Sanofi Aventis [Francia y Canadá], Boehringer Ingelheim [Alemania y Canadá], Servier y GlaxoSmithKline), Novartis y King Pharma, y ​​organizaciones nacionales o locales en los países participantes.

10.1016/S2468-2667(17)30141-X

pdf

http://dx.doi.org/10.1016/S2468-2667(17)30141-X

Public, Environmental & Occupational Health

Salud Pública y Ambiental

Sistema Cardiovascular y Cardiaco

Economía

WOS:000425588900010

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

Artículo original

version publicada

ELSEVIER SCI LTD

LANCET PUBLIC HEALTH

Salud pública, ambiental y ocupacional

2468-2667

en

Heart and Stroke Foundation#Ontario Ministry of Health and Long-Term Care#AstraZeneca [Canada]#Sanofi Aventis [France and Canada]#Boehringer Ingelheim [Germany amd Canada]#Servier, and GlaxoSmithKline#Novartis#King Pharma

Population Health Research Institute

Canadian Institutes of Health Research

Heart and Stroke

Canadian Institutes of Health Research Strategy for Patient Oriented Research

Ministry of Health and Long-Term Care

AstraZeneca (Canada)

Sanofi Aventis (France)

Sanofi Aventis (Canada)

Boehringer Ingelheim (Germany)

Boehringer Ingelheim (Canada)

Servier

GlaxoSmithKline

Novartis

King Pharma

Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Canadian Institutes of Health Research Strategy for Patient Oriented Research through the Ontario SPOR Support Unit, the Ontario Ministry of Health and Long-Term Care, pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi Aventis [France and Canada], Boehringer Ingelheim [Germany amd Canada], Servier, and GlaxoSmithKline), Novartis and King Pharma, and national or local organisations in participating countries.

pdf

dorada#verde

acceso abierto

acceso abierto

CC BY-NC-ND 4.0

2179

2184